Repeated Treatments with Ingenol Mebutate Prevents Progression of UV-Induced Photodamage in Hairless Mice

Andrés Már Erlendsson1*, Daniel Thaysen-Petersen1, Christiane Bay1, Andreas Hald2, Kresten Skak2, John Robert Zibert2, Uwe Paasch3, Hans Christian Wulf1, Merete Haedersdal1

1 Department of Dermatology, Bispebjerg University Hospital, Copenhagen, Denmark, 2 Leo Pharma A/S, Ballerup, Denmark, 3 Department of Dermatology, Division of Aesthetics and Laserdermatology, University of Leipzig, Leipzig, Germany

* andres.erlendsson@gmail.com

Abstract

Background and Aim
Ingenol mebutate (IngMeb) is an effective treatment for actinic keratosis. In this study, we hypothesized that repeated treatments with IngMeb may prevent progression of UV-induced photodamage, and that concurrent application of a corticosteroid may reduce IngMeb-induced local skin responses (LSR).

Methods
Hairless mice (n = 60; 3 groups of 20 mice) were irradiated with solar simulated ultraviolet radiation (UVR) throughout the study. Five single treatments with IngMeb were given at 4-week intervals (Days 21, 49, 77, 105, and 133). Clobetasol propionate (CP) was applied once daily for 5 days prior to each IngMeb application, as well as 6 h and 1 day post treatment. One week after IngMeb treatment No. 1, 3, and 5 (Days 28, 84, and 140), biopsies from four mice in each group were collected for histological evaluation of UV-damage on a standardized UV-damage scale (0–12). LSR (0–24) were assessed once daily (Days 1–7) after each IngMeb treatment.

Results
IngMeb prevented progression of photodamage in terms of keratosis grade, epidermal hypertrophy, dysplasia, and dermal actinic damage with a lower composite UV-damage score on day 140 (UVR 10.25 vs. UVR+IngMeb 6.00, p = 0.002) compared to UVR alone. IngMeb induced LSR, including erythema, flaking, crusting, bleeding, vesiculation, and ulceration. Concurrent CP increased LSR (max LSR Tx 1–5: UVR+IngMeb+CP 3.6–5.5 vs.
Conclusion

Repeated field-directed treatments with IngMeb prevent progression of cutaneous photodamage in hairless mice, while CP cannot be used to alleviate IngMeb-induced LSR. The findings suggest that IngMeb may potentially serve as a prophylactic treatment for UV-induced tumors.

Introduction

Non-melanoma skin cancer (NMSC) is the most commonly diagnosed cancer globally and is primarily constituted by basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) [1]. Ultraviolet radiation (UVR) is account for 90% of BCC and SCC and acts as a complete carcinogen capable of tumor initiation, promotion, and progression [2].

UVB (290–320 nm) is directly absorbed by DNA bases, producing photolesions such as cyclobutane pyrimidine dimers (CPD) and 6–4 photoproducts [3]. If not repaired, these photolesions cause signature UV mutations i.e. ‘C to T’ or ‘CC to TT’ [3]. In addition, UVR (UVA 320–400 nm and UVB), absorbed by various skin chromophores, may result in production of reactive oxygen species (ROSs) [4]. Through oxidative stress, ROSs are believed to cause indirect DNA damage, and may play a role in tumor promotion [5]. Through continuous oxidative stress and accumulation of mutations, processes like proliferation, differentiation, and apoptosis fail; unresponsive to normal cell-signaling pathways, aberrant cells may grow into dysplastic colonies and eventually undergo malignant progression [6].

Ingelone mebutate (IngMeb) is a topical drug, approved for field-treatment of actinic keratoses (AKs) [7]. IngMeb induces loss of plasma and mitochondrial membrane potential in keratinocytes, facilitating Ca²⁺ influx, which results in swelling and induction of cell death by necrosis and apoptosis [8,9]. IngMeb also activates various Protein Kinase C (PKC) isomers, especially PKC-δ, which is suggested to induce apoptosis [10,11], while also increasing innate-immune surveillance by neutrophil recruitment [10–14]. In a murine study, application of IngMeb to photodamaged skin resulted in a 70% reduction of p53-mutated patches as well as a 70% reduction in the number of tumors that subsequently emerged [15]. As IngMeb is successful in reversing pre-existing actinic damage, repeated treatments with IngMeb may hold promise in preventing progression of UV-induced photodamage.

A prerequisite for prophylactic treatments is minimal side effects. IngMeb is however known to induce acute inflammation of varying intensity and minimizing the inflammation is of importance before IngMeb can be considered for prophylactic purposes [7,16]. Clobetasol propionate (CP) is a potent glucocorticoid with immunosuppressive, anti-inflammatory, and vasoconstrictive properties [17]. Topical application of dexamethasone has previously been found to prevent IngMeb-induced neutrophil invasion, and CP may similarly be used to alleviate IngMeb-induced inflammation [18].

In this study, we hypothesized that repeated treatments with IngMeb may prevent progression of UV damage, and that application of a corticosteroid may reduce IngMeb-induced local skin responses (LSR).
Methods

Animals

A total of 60 hairless, immunocompetent C3.Cg/TifBomTac mice of female gender (Taconic, Lille Skensved, Denmark) were randomized to 3 groups and tattooed with consecutive numbers. Each group of 20 mice was accommodated in separate cages with ad libitum access to water and food. The animal facility was kept at a 12 h light-dark cycle and the animals were weighted monthly. During the entire study period, the well-being of the animals was monitored daily; mice showing any signs of discomfort, distress or pain, including reduced mobility, inactivity, abnormal posture, lack of grooming, or ulceration exceeding 10 mm in diameter were euthanized. Euthanasia was conducted through cervical dislocation or through asphyxiation with CO₂. The study followed national guidelines for laboratory animal welfare and was approved by The Animal Experimental Inspectorate (J.nr. 2014-15-0201-00096).

Study Set-Up

Interventions are presented in Table 1. Mice were irradiated with solar simulated UVR 3 times per week during the study period. Five single treatments with IngMeb were given at 4-week intervals (Days 21, 49, 77, 105, 133). Concurrent CP ointment was applied pre and post IngMeb treatment. One week after IngMeb treatment No. 1, 3, and 5 (Days 28, 84, 140), four mice from each group were euthanized and skin biopsies were taken from the backs of the animals. The primary objective was to follow the histological development of UV-damage in the

| Week | Group 1 UVR (n = 20) | Group 2 UVR+IngMeb (n = 20) | Group 3 UVR+IngMeb+CP (n = 20) |
|------|----------------------|-----------------------------|--------------------------------|
| 1    | 3x3 SED              | 3x3 SED                     | 3x3 SED                        |
| 2    | 3x3 SED              | 3x3 SED                     | 3x3 SED                        |
| 3    | 3x3 SED              | 3x3 SED Tx1 IngMeb          | 3x3 SED Tx1 IngMeb+CP          |
| 4    | -                    | 4 mice                      | 4 mice                         |
| 5    | 3x3 SED              | 3x3 SED                     | 3x3 SED                        |
| 6    | 3x3 SED              | 3x3 SED                     | 3x3 SED                        |
| 7    | 3x3 SED              | 3x3 SED Tx2 IngMeb          | 3x3 SED Tx2 IngMeb+CP          |
| 8    | -                    | -                           | -                              |
| 9    | 3x3 SED              | 3x3 SED                     | 3x3 SED                        |
| 10   | 3x3 SED              | 3x3 SED                     | 3x3 SED                        |
| 11   | 3x3 SED              | 3x3 SED Tx3 IngMeb          | 3x3 SED Tx3 IngMeb+CP          |
| 12   | -                    | 4 mice                      | 4 mice                         |
| 13   | 3x3 SED              | 3x3 SED                     | 3x3 SED                        |
| 14   | 3x3 SED              | 3x3 SED                     | 3x3 SED                        |
| 15   | 3x3 SED              | 3x3 SED Tx4 IngMeb          | 3x3 SED Tx4 IngMeb+CP          |
| 16   | -                    | -                           | -                              |
| 17   | 3x3 SED              | 3x3 SED                     | 3x3 SED                        |
| 18   | 3x3 SED              | 3x3 SED                     | 3x3 SED                        |
| 19   | 3x3 SED              | 3x3 SED Tx5 IngMeb          | 3x3 SED Tx5 IngMeb+CP          |
| 20   | -                    | 4 mice                      | 4 mice                         |

In group 3, CP was applied once daily for five days prior to each IngMeb treatment, 6 h after, and 1 day after IngMeb treatment, in total 7 applications.

UVR = ultraviolet radiation, IngMeb = Ingenol Mebutate, CP = clobetasol propionate, SED = standard erythema dose, Tx = Treatment.

doi:10.1371/journal.pone.0162597.t001
skin on a standardized UV-damage scale. Primary end-point was UV-damage score on Days 28, 84, 140. Biopsies from a control mouse, not receiving UVR were used as a normal skin reference. The secondary objective was to investigate the effect of concurrent CP application on IngMeb-induced LSR. Accordingly, secondary endpoint was LSR-scores during all IngMeb treatments. Mice were followed for up to 140 days.

Solar simulated ultraviolet radiation

UVR was given with a UV6 tube (Waldmann, Wheeling, IL, USA) placed between five Bellarium-S SA-1-12 tubes (Wolff System, Atlanta, Georgia, USA) with a maximum wavelength of 365 nm and 5.9% in the UV-B spectrum [19]. UVR was administered as 3 standard erythema doses (SEDs) three times weekly. The UV-dose was measured using a spectroradiometer (SolaTell Sola-Hazard 4D Controls Ltd., Cornwall, UK) and UVR-exposure time adjusted continuously to correspond to 3 SED. To allow recovery from IngMeb treatments, each treatment was followed by a one-week pause from UVR.

Ingenol Mebutate & Clobetasol Propionate

IngMeb-gel (120 μl; Picato® 0.015%, LEO Pharma, Ballerup, Denmark) was applied on the entire dorsal skin of the mice, from neck to tail. CP-ointment (25 μl; Dermovat® 0.05%, GlaxoSmithKline Pharma, Brentford, United Kingdom) was correspondingly applied on the entire dorsal skin of the mice once daily for five days prior to each IngMeb treatment, 6 h after, and 1-day after IngMeb treatment, in total 7 applications.

Histological preparation

After euthanasia, biopsies from the dorsal skin of the mice were taken at pre-determined positions, fixed in 4% formalin, embedded in paraffin, and cut in 5μm slides. Slides were stained with hematoxylin and eosin for blinded UV-damage evaluation.

Outcome measurements

Histological evaluation of UV-damage. UV-damage evaluations were based on standardized assessments of UV-damage on a ‘UV-damage score scale’. The scale is based on changes known to emerge in hairless mice in response to UVR and have been established previously [20–23]. The scale was tested on histology slides from non-UV-irradiated murine skin and UV-irradiated murine skin before being used for blinded evaluation in the study. The scale evaluates signs of UV-damage in hairless mice, and includes appraisal of stratum corneum, epidermis, and dermis. Assessments were conducted by a blinded dermatopathologist (U.P.) on a categorical scale from 0–3 evaluating (i) keratosis grade of stratum corneum (0 orthokeratotic, 1 focal hyperkeratosis, 2 generalized hyperkeratosis, 3 parakeratosis), (ii) thickness of epidermis (0 3–4 cell layers, 1 5–7 cell layers, 2 8–10 cell layers, 3 10+ cell layers), (iii) dysplasia of epidermis (0 none, 1 present in lower 1/3, 2 present in lower 2/3, 3 present in the entire epidermis), and (iv) dermal actinic damage (0 none, 1 focal, upper papillary layer, 2 generalized, upper papillary layer, 3 reticular layer). The composite UV-score represented the sum of all sub-evaluations (0–12), where higher numbers indicated more severe UV-damage.

Local skin responses (LSR). During all five IngMeb treatments, LSR was registered at baseline and 1-, 2-, 3-, 4-, 5-, 6-, and 7 days after treatment. The LSR evaluation consisted of separate evaluations of erythema, flaking, crusting, vesiculation, bleeding, and ulceration on a scale from 0–4 as described by Rosen et al [16]. In the current study, evaluations of swelling were not conducted but replaced with evaluations of bleeding. The composite LSR-score
represented the sum of all sub-evaluations (0–24), where higher numbers indicated more severe skin reactions.

Statistics

UV-damage score and LSR-responses were compared using unpaired t-test and Spearman correlation was used to evaluate relation between UV-damage and time. P-values were 2-sided and considered statistically significant when less than 0.05. Statistical analyses were performed in SPSS version 23 for Mac (IBM Corporation, Armonk, NY, USA).

Results

UV damage

In mice receiving UVR alone, keratosis grade, epidermal hypertrophy, dysplasia, and actinic dermal damage increased over time (Table 2, Fig 1); composite UV-damage score at day 28 was 4.50, which increased to 6.67 at day 84, and 10.25 at day 140 ($R_s = 0.82, p = 0.002$). IngMeb treatments prevented progression of photodamage in terms of keratosis grade, epidermal hypertrophy, dysplasia, and dermal actinic damage; composite UV-damage score was 3.50, 5.00, and 6.00 at day 28, 84, and 140, respectively, (UVR vs. UVR+IngMeb day 140, $p = 0.002$; Table 2, Fig 1).

Concurrent CP applications potentiated the UV-protective effect of IngMeb (Table 2, Fig 1). No progression in photodamage was observed during the 140 days of UVR exposure ($R_s = -0.03, p = 0.936$). Composite UV-damage score was 3.00 at day 28, 3.75 at day 84, and 3.00 at day 140, reaching statistical significance at day 140 (UVR vs. UVR+IngMeb+CP, $p < 0.001$; UVR+IngMeb vs. UVR+IngMeb+CP, $p = 0.014$).

Table 2. Ultraviolet damage scores 1 week after ingenol mebutate treatment No. 1, 3 and 5.

| Group | UV-damage score | Day 28 | Day 84 | Day 140 |
|-------|-----------------|--------|--------|---------|
| UVR   | Keratosis grade | 4.50   | 1.00   | 1.67    | 2.75 |
|       | Epidermal thickness | 0.75   | 0.75   | 1.67    | 2.50 |
|       | Dysplasia       | 1.25   | 1.25   | 1.33    | 2.25 |
|       | Dermal actinic damage | 1.50   | 1.50   | 2.00    | 2.75 |
| UVR + IngMeb | Keratosis grade | 3.50   | 0.75   | 1.00   | 1.75 |
|       | Epidermal thickness | 0.75   | 0.75   | 1.00   | 1.00 |
|       | Dysplasia       | 1.25   | 1.25   | 1.50   | 1.00 |
|       | Dermal actinic damage | 0.75   | 0.75   | 1.50   | 2.25 |
| UVR + IngMeb+CP | Keratosis grade | 3.00   | 1.00   | 0.75   | 0.00 |
|       | Epidermal thickness | 0.50   | 0.50   | 0.75   | 0.67 |
|       | Dysplasia       | 0.75   | 0.75   | 1.00   | 1.00 |
|       | Dermal actinic damage | 0.50   | 0.50   | 1.25   | 1.33 |

UVR = ultraviolet radiation, IngMeb = Ingenol Mebutate, CP = clobetasol propionate

* Spearman Correlation, UV-damage/time.
** Statistically significant.

doi:10.1371/journal.pone.0162597.t002
Fig 1. Histology. The figure depicts histological slides from mice exposed to ultraviolet radiation (UVR; a, b and c), 2) UVR and ingenol mebutate (UVR + IngMeb; d, e, and f) 3) UVR, IngMeb and clobetasol propionate (UVR + IngMeb = CP; g, h, and i) and 4) normal skin (j). Histological findings disclose that keratosis grade, epidermal hypertrophy, dysplasia, and actinic dermal damage increased over time in mice receiving UVR alone ($R_s = 0.82$, $p = 0.002$), while repeated treatments with ingenol mebutate prevented progression of photodamage (Day 140; UVR 10.25 vs. UVR+IngMeb 6.00, $p = 0.002$). Concurrent treatments with CP potentiated the prophylactic effect of IngMeb with UV-damage scores similar to normal skin at day 140 (UVR+IngMeb+CP 3.00, Normal skin 3.00). * dermal actinic damage; ** dysplasia present in lower 2/3 of epidermis and an absent basal layer with the presence of a Zytoid body; *** parakeratosis.

doi:10.1371/journal.pone.0162597.g001
Local skin responses

LSR included erythema, flaking, crusting, bleeding, vesiculation, and ulceration. Maximal composite LSRs-score were of moderate intensity in mice treated with IngMeb alone (max LSR treatment 1–5: 3.6–5.5; Table 3), while concurrent treatment with CP increased LSR significantly during IngMeb in three out of five treatments (Table 3, Fig 2). CP increased the prevalence of intracutaneous bleedings in treatment 1 and 2 (p < 0.037) and in areas where such bleedings occurred, wounds with crusting, flaking, and subsequently ulceration appeared.

Evolution of individual responses during first IngMeb treatment is presented in Fig 2; erythema, bleeding, and vesiculation developed rapidly after IngMeb application peaking on day 1. Flaking and crusting emerged on day 2, culminating on day 3 while ulceration had a delayed onset and reached peak intensity on day 5. The skin normalized by day 10 post-treatment.

Discussion

This study is the first to demonstrate that repeated field-directed treatments with IngMeb prevent progression of cutaneous photodamage in hairless mice, suggesting that IngMeb may serve as prophylactic treatment for UV-induced tumors.

Incidence rates of NMSC in Europe have increased steadily since the 1960s and more than tripled over the last 50 years [1]. As UVR cannot be completely avoided, chemopreventative treatments are needed to complement primary skin cancer prevention. Various systemic and topical formulations have been studied for this purpose, including retinoids, non-steroidal anti-inflammatory drugs, nicotinamide and difluoromethylornithine, but the necessity of daily use render them cumbersome in practice. Herein, we demonstrate that monthly treatments with IngMeb prevent progression of photodamage, including development of hyperkeratosis, epidermal hypertrophy, dysplasia, and dermal actinic damage. In another murine study, such chemoprophylaxis was shown to postpone tumor formation (from 168 to 189; p = 0.025),

Table 3. Maximum local skin responses (LSR) in areas treated with IngMeb and IngMeb+CP.

| Group 2—UVR + IngMeb | Treatment 1 LSR | Treatment 2 LSR | Treatment 3 LSR | Treatment 4 LSR | Treatment 5 LSR |
|----------------------|----------------|----------------|----------------|----------------|----------------|
| Erythema             | 1.2            | 1.0            | 1.0            | 1.0            | 1.5            |
| Flaking              | 1.0            | 0.9            | 1.2            | 0.9            | 1.5            |
| Crusting             | 0.9            | 0.9            | 1.4            | 0.9            | 1.0            |
| Pustulation          | 0.0            | 0.0            | 0.1            | 0.0            | 0.3            |
| Ulceration           | 0.1            | 0.2            | 0.0            | 0.3            | 0.8            |
| Bleeding             | 0.1            | 0.2            | 0.0            | 0.3            | 0.8            |
| Group 3—UVR+ IngMeb+CP |                |                |                |                |                |
| Erythema             | 2.4            | 1.3            | 1.0            | 1.0            | 2.0            |
| Flaking              | 1.7            | 1.9            | 1.3            | 1.4            | 1.5            |
| Crusting             | 1.9            | 2.1            | 1.3            | 1.1            | 1.8            |
| Pustulation          | 0.8            | 0.3            | 0.1            | 0.5            | 1.0            |
| Ulceration           | 0.6            | 0.9            | 0.0            | 0.1            | 0.8            |
| Bleeding             | 0.6            | 0.9            | 0.0            | 0.1            | 0.8            |
| Effect of CP: P-value, comparing UVR+IngMeb vs. UVR+IngMeb = CP | <0.001* | <0.001* | 0.886 | 0.015* | 0.376 |

UVR = ultraviolet radiation, IngMeb = Ingenol Mebutate, CP = clobetasol propionate,
*Statistically significant.

doi:10.1371/journal.pone.0162597.t003
Fig 2. Local skin responses. The figure depicts the evolution of individual local skin responses (LSR) in mice treated with ingenol mebutate alone (IngMeb; A) and concurrent clobetasol (IngMeb+CP: B). Erythema, bleeding, and vesiculation developed rapidly after IngMeb application peaking on day 1. Flaking and crusting emerged on day 2, culminating on day 3 while ulceration had a delayed onset and reached peak intensity on day 5. Concurrent CP application did not alleviate the LSR but exacerbated all individual responses, including erythema, bleeding, vesiculation, flaking, crusting and ulceration. The skin was normalized by day 10 post-treatment in both IngMeb and IngMeb+CP treated mice.

doi:10.1371/journal.pone.0162597.g002
suggesting that prevention of early actinic damage may translate into effective prophylactic treatments for UV-induced tumors [24]. Additionally, the study substantiates the evidence of IngMeb as a field-directed treatment, not only targeting pre-existing AKs but preventing progression of UV-damage in surrounding pre-cancerous skin. A third murine study investigating IngMeb treatment of pre-cancerous skin, showed a 70% reduction in tumor formation [15]. The authors argued that IngMeb-induced necrosis and apoptosis of the epidermis and subsequent re-epithelialization with non-irradiated keratinocytes from bordering hair follicles was the major mechanism behind the prophylactic effect. However, previous murine studies conducted in C3.Cg/TifBomTac species have suggested that murine tumors often originate from hair follicles [25]. In addition to epidermal renewal, IngMeb also activates Protein Kinase C-delta (PKC-δ) which has been found to induce apoptosis in cancer cell lines [10,26] and induce upregulation of neutrophil mediators, (IL-8, TNF-α, ICAM-1, and E-selectin), resulting in massive neutrophil invasion to the skin [27]. Recent investigations have demonstrated that the immune infiltration is not confined to the epidermis, but reaches deep into the hair follicles and IngMeb may thus be able to eradicate aberrant cells in profound parts of their structure. Through a combination of epidermal renewal and immune activation, repeated treatments with IngMeb are believed to provide the observed photoprevention as demonstrated herein.

This study is the first to document the evolution of LSR after a single IngMeb treatment, finding that the intensity of individual responses was time-dependent. Vesiculation and bleeding appeared immediately after IngMeb application. At cessation of bleeding and vesiculation, flaking and crusting emerged and cumulated before ulceration peaked. Erythema was present from day 1 and decreased gradually until the skin normalization by day 10. Observed reactions may be too severe to justify prophylactic use, and in order for IngMeb to gain clinical impact as a prophylactic remedy, the LSR must be kept at a minimum. Previous studies have demonstrated that corticosteroids can block IngMeb-induced neutrophil invasion, and concurrent CP was thus believed to alleviate LSR[18]. Contrary to our hypothesis, CP failed to alleviate LSR and in contrast generated more severe LSR. Murine studies have previously argued that if IngMeb comes in contact with the dermal capillary plexus, disruption of the vasculature may cause intracutaneous bleeding [13,18]. In mice treated with IngMeb, bleeding was not common, but CP increased the prevalence of intracutaneous bleedings and in areas where such bleedings occurred, wounds with crusting and flaking appeared. Since murine epidermis is only 3-cell layer thick, the pre-treatment with CP may have disrupted the skin barrier and allowed IngMeb to come in contact with the dermal vasculature. Alternatively, the application of CP-ointment 6h after IngMeb may have had an occlusive effect, which again is known to increase cutaneous uptake and may have caused the observed bleedings. The LSR are thus likely increased in CP-treated mice due to a deeper penetration of IngMeb; CP’s effect on inflammation is in this instance unclear, as a potential block of neutrophil invasion is likely overshadowed by the increased LSR caused by the intracutaneous bleeding. Additionally, a recent clinical trial examined CP effect on IngMeb-induced inflammation after three daily applications of IngMeb in patients with AKs [28]; the study found no alleviating effect of CP, and it is thus feasible that CP has no impact on IngMeb-induced LSR. However, in the clinical trial, CP was applied after finalized IngMeb treatment and earlier initiation of CP applications needs to be investigated before final conclusions can be drawn.

The hairless mouse model is widely employed for investigations of photocarcinogenesis [29]. The C3.Cg/TifBomTac mice have a very low incidence of spontaneous skin tumors and their response to UVR is similar to humans, developing squamous cell carcinomas and having the ability to tan. Still, major morphological differences between mouse and human skin render murine skin more permeable to most topical agents, and findings regarding prevention of photodamage, LSR, and effects of CP cannot be directly extrapolated to humans. Additionally,
prevention of photodamage is not equivalent to NMSC prophylaxis; the impact of photodamage prevention on postponement of cutaneous cancers remains to be investigated.

In conclusion, repeated field-directed treatments with IngMeb prevent progression of cutaneous photodamage in hairless mice, while CP cannot be used to alleviate IngMeb-induced LSR. The findings suggest that IngMeb may potentially serve as a prophylactic treatment for UV-induced BCC and SCC.

Supporting Information
S1 File. Database with raw data.
(XLSX)

Author Contributions

Conceptualization: AME UP HCW MH.
Formal analysis: AME AH KS JRZ UP HCW MH.
Funding acquisition: AH KS JRZ HCW MH.
Investigation: AME DTP CB.
Methodology: AME UP HCW MH.
Project administration: AME MH.
Resources: AME AH KS JRZ UP HCW MH.
Supervision: KS JRZ UP HCW MH.
Validation: AME UP HCW MH.
Visualization: AME UP HCW MH.
Writing – original draft: AME MH.
Writing – review & editing: AME DTP CB AH KS JRZ UP HCW MH.

References
1. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012; 166: 1069–1080. doi:10.1111/j.1365-2133.2012.10830.x PMID: 22251204
2. Rosso S, Zanetti R, Martinez C, Tormo MJ, Schraub S, Sancho-Garnier H, et al. The multicentre south European study “Helios”. II: Different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. Br J Cancer. 1996; 73: 1447–54. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2074492&tool=pmcentrez&rendertype=abstract PMID: 8645596
3. De Grujil FR, Van Kranen HJ, Mullenders LHF. UV-induced DNA damage, repair, mutations and oncogenic pathways in skin cancer. J Photochem Photobiol B Biol. 2001; 63: 19–27.
4. Rass K, Reichrath J. UV damage and DNA repair in malignant melanoma and nonmelanoma skin cancer. Adv Exp Med Biol. 2008; 624: 162–78. doi: 10.1007/978-0-387-77574-6_13 PMID: 18348455
5. Bech-Thomsen N. Aspects of exposure to UVA tanning sources. Carcinogenic effect in mice and melanogenic effect in man and mice. Dan Med Bull. 1987; 44: 242–56. Available: http://www.ncbi.nlm.nih.gov/pubmed/9233545 PMID: 9233545
6. Hanahan D, Weinberg R a. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646–74. doi: 10.1016/j.cell.2011.02.013 PMID: 21376230
7. Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol Mebutate Gel for Actinic Keratosis. N Engl J Med. 2012; 366: 1010–19. doi: 10.1056/NEJMoa1111170 PMID: 22417254
8. Ogbourne SM, Suhrbier A, Jones B, Cozzi S-J, Boyle GM, Morris M, et al. Antitumor Activity of 3-Ingeryl Angelate: Plasma Membrane and Mitochondrial Disruption and Necrotic Cell Death. Cancer Res. 2004; 64: 2833–2839. doi: 10.1158/0008-5472.CAN-03-2837 PMID: 15087400

9. Stahlhut M, Bertelsen M, Heyer-Hansen M, Svendsen N, Eriksson AH, Lord JM, et al. Ingenol Mebutate-Induced Cell Death Patterns in Normal and Cancer Epithelial Cells. J Drugs Dermatol. 2012; 11: 1181–1192.

10. Serova M, Ghoul A, Benhadji K a, Faivre S, Le Tourneau C, Cvitkovic E, et al. Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells. Mol Cancer Ther. 2008; 7: 915–22. doi: 10.1158/1535-7183.MCT-07-2060 PMID: 18413805

11. Hampson P, Chahal H, Khanim F, Hayden R, Mulder A, Assi LK, et al. PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. Blood. 2005; 106: 1362–8. doi: 10.1182/blood-2004-10-1177 PMID: 15845901

12. Hampson P, Kavanagh D, Smith E, Wang K, Lord JM, Ed Rainger G. The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-delta dependent manner. Cancer Immunol Immunother. 2008; 57: 1241–51. doi: 10.1007/s00262-008-0458-9 PMID: 18265980

13. Challacombe JM, Suhrbier A, Parsons PG, Jones B, Hampson P, Kavanagh D, et al. Neutrophils Are a Key Component of the Antitumor Efficacy of Topical Chemotherapy with Ingenol-3-angelate. J Immunol. 2006; 177: 8123–8132. PMID: 17114487

14. Freiberger SN, Cheng PF, Iotzova-Weiss G, Neu J, Liu Q, Dziunycz P, et al. Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2. Mol Cancer Ther. 2015; 14: 2132–42. doi: 10.1158/1535-7183.MCT-15-0023-T PMID: 25163599

15. Cozzi S-J, Ogbourne SM, James C, Reibel HG, de Grujil FR, Ferguson B, et al. Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches. J Invest Dermatol. 2012; 132: 1263–71. doi: 10.1038/jid.2011.418 PMID: 22189786

16. Rosen R, Marmor E, Anderson L, Welburn P, Katsamas J. A new, objective, quantitative scale for measuring local skin responses following topical actinic keratosis therapy with ingenol mebutate. Dermatol Ther (Heidelb). 2014; 4: 207–19. doi: 10.1007/s13555-014-0059-9

17. Schafer-Korting M, Kleuser B, Ahmed M, Holtje H-D, Korting HC. Glucocorticoids for human skin: new aspects of the mechanism of action. Skin Pharmacol Physiol. 2015; 18: 103–14. doi: 10.1159/000355580 PMID: 15997682

18. Li L, Shukla S, Lee A, Garfield SH, Maloney DJ, Ambudkar S V, et al. The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. Cancer Res. 2010; 70: 4509–19. doi: 10.1158/0008-5472.CAN-09-4303 PMID: 20480505

19. Lerche CM, Sepehri M, Poulsen T, Wulf HC. Black tattoos protect against UVR-induced skin cancer in mice. Photodermatol Photoimmunol Photomed. 2015; doi: 10.1111/gap.12181

20. Wulf HC, Poulsen T, Brodhagen H, Hou-Jensen K. Sunscreens for delay of ultraviolet induction of skin tumors. J Am Acad Dermatol. 1982; 7: 194–202. Available: http://www.ncbi.nlm.nih.gov/pubmed/6982289 PMID: 6982289

21. Montagna W, Chase HB, Brown PJ. The skin of hairless mice. J Invest Dermatol. 1954; 25: 259–270. PMID: 13201816

22. Kligman LH, Kligman a M. Histogenesis and progression in ultraviolet light-induced tumors in hairless mice. J Natl Cancer Inst. 1981; 67: 1289–93. Available: http://www.ncbi.nlm.nih.gov/pubmed/6947111 PMID: 6947111

23. Kaarsen LL, Poulsen TD, de Fine Olivierius F W H. Mast cells and elastosis in ultraviolet-irradiated hairless mice. Photodermatol Photoimmunol Photomed. 1995; 11: 1–5. PMID: 7654560

24. Erlendsson AM, Thaysen-Petersen D, Bay C, Lerche CM, Philipsen PA, Wulf HC, et al. Repeated treatments with ingenol mebutate for prophylaxis of UV-induced squamous cell carcinoma in hairless mice. J Photochem Photobiol B. 2016; 163: 144–149. doi: 10.1016/j.jphotobiol.2016.08.022 PMID: 27567085

25. Faurschou A, Haedersdal M, Poulsen T, Wulf HC. Squamous cell carcinoma induced by ultraviolet radiation originates from cells of the hair follicle in mice. Exp Dermatol. 2007; 16: 485–93. doi: 10.1111/j.1600-0625.2007.00511.x PMID: 17518988

26. Yadav V, Yanez NC, Fenton SE, Denning MF. Loss of protein kinase C delta gene expression in human squamous cell carcinomas: a laser capture microdissection study. Am J Pathol. 2010; 176: 1091–6. doi: 10.2353/ajpath.2010.090816 PMID: 20093486
27. Kedei N, Lundberg DJ, Toth A, Welburn P, Garfield SH, Blumberg PM. Characterization of the Interaction of Ingenol 3-Angelate with Protein Kinase C. Cancer Res. 2004; 64: 3243–3255. doi:10.1158/0008-5472.CAN-03-3403 PMID: 15126366

28. Erlendsson AM, Karmisholt KE, Haak CS, Stender I-M, Haedersdal M. Topical corticosteroid has no influence on inflammation or efficacy after ingenol mebutate treatment of grade I to III actinic keratoses (AK): A randomized clinical trial. J Am Acad Dermatol. 2016; doi:10.1016/j.jaad.2015.11.034

29. Mukhtar H, Forbes PD, Ananthaswamy HN. Photocarcinogenesis—models and mechanisms. Photodermatol Photoimmunol Photomed. 1999; 15: 91–5. Available: http://www.ncbi.nlm.nih.gov/pubmed/10404716 PMID: 10404716